Schizophrenia drug discovery and development in an evolving era: Are new drug targets fulfilling expectations?
出版年份 2015 全文链接
标题
Schizophrenia drug discovery and development in an evolving era: Are new drug targets fulfilling expectations?
作者
关键词
-
出版物
JOURNAL OF PSYCHOPHARMACOLOGY
Volume 29, Issue 2, Pages 230-238
出版商
SAGE Publications
发表日期
2015-01-14
DOI
10.1177/0269881114565806
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Emerging Biology of PDE10A
- (2014) Lindsay Wilson et al. CURRENT PHARMACEUTICAL DESIGN
- In Vivo Assessment and Dosimetry of 2 Novel PDE10A PET Radiotracers in Humans: 18F-MNI-659 and 18F-MNI-654
- (2014) O. Barret et al. JOURNAL OF NUCLEAR MEDICINE
- Phosphodiesterase 10A PET Radioligand Development Program: From Pig to Human
- (2014) C. Plisson et al. JOURNAL OF NUCLEAR MEDICINE
- Normalizing Effects of EVP-6124, an Alpha-7 Nicotinic Partial Agonist, on Event-Related Potentials and Cognition
- (2014) SHELDON H. PRESKORN et al. Journal of Psychiatric Practice
- De novo mutations in schizophrenia implicate synaptic networks
- (2014) Menachem Fromer et al. NATURE
- A polygenic burden of rare disruptive mutations in schizophrenia
- (2014) Shaun M. Purcell et al. NATURE
- Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
- (2014) David Cook et al. NATURE REVIEWS DRUG DISCOVERY
- Advances in targeting cyclic nucleotide phosphodiesterases
- (2014) Donald H. Maurice et al. NATURE REVIEWS DRUG DISCOVERY
- The Phosphodiesterase 10 Positron Emission Tomography Tracer, [18F]MNI-659, as a Novel Biomarker for Early Huntington Disease
- (2014) David S. Russell et al. JAMA Neurology
- Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia
- (2014) Daniel Umbricht et al. JAMA Psychiatry
- Antipsychotic Treatment Resistance in Schizophrenia Associated with Elevated Glutamate Levels but Normal Dopamine Function
- (2013) Arsime Demjaha et al. BIOLOGICAL PSYCHIATRY
- A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia
- (2013) David H Adams et al. BMC Psychiatry
- PET imaging shows loss of striatal PDE10A in patients with Huntington disease
- (2013) R. Ahmad et al. NEUROLOGY
- Phosphodiesterase 10A inhibitor MP-10 effects in primates: Comparison with risperidone and mechanistic implications
- (2013) Subramaniam Uthayathas et al. NEUROPHARMACOLOGY
- Panel and Study Groups
- (2013) NEUROPSYCHOPHARMACOLOGY
- Antagonism of the adenosine A2A receptor attenuates akathisia-like behavior induced with MP-10 or aripiprazole in a novel non-human primate model
- (2013) Carina J. Bleickardt et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo
- (2013) Virginia L. Stauffer et al. SCHIZOPHRENIA RESEARCH
- Impaired GABAergic Neurotransmission in Schizophrenia Underlies Impairments in Cortical Gamma Band Oscillations
- (2013) James M. McNally et al. Current Psychiatry Reports
- Update on Typical and Atypical Antipsychotic Drugs
- (2012) Herbert Y. Meltzer Annual Review of Medicine
- Synaptic and Extrasynaptic NMDA Receptors Are Gated by Different Endogenous Coagonists
- (2012) Thomas Papouin et al. CELL
- Phosphodiesterase 10A inhibitors: a 2009 – 2012 patent update
- (2012) Jan Kehler EXPERT OPINION ON THERAPEUTIC PATENTS
- A Multicenter, Add-On Randomized Controlled Trial of Low-Dosed-Serine for Negative and Cognitive Symptoms of Schizophrenia
- (2012) Mark Weiser et al. JOURNAL OF CLINICAL PSYCHIATRY
- HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity
- (2012) Mitsumasa Kurita et al. NATURE NEUROSCIENCE
- The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey
- (2012) Sean M. Smith et al. NEUROPHARMACOLOGY
- Glycine Transporter Type 1 Occupancy by Bitopertin: a Positron Emission Tomography Study in Healthy Volunteers
- (2012) Meret Martin-Facklam et al. NEUROPSYCHOPHARMACOLOGY
- Capturing the Angel in "Angel Dust": Twenty Years of Translational Neuroscience Studies of NMDA Receptor Antagonists in Animals and Humans
- (2012) B. Moghaddam et al. SCHIZOPHRENIA BULLETIN
- NMDA Receptor Hypofunction, Parvalbumin-Positive Neurons, and Cortical Gamma Oscillations in Schizophrenia
- (2012) G. Gonzalez-Burgos et al. SCHIZOPHRENIA BULLETIN
- Poster #212 RESULTS OF A PHASE 2A PROOF-OF-CONCEPT TRIAL WITH A PDE10A INHIBITOR IN THE TREATMENT OF ACUTE EXACERBATION OF SCHIZOPHRENIA
- (2012) Nicholas DeMartinis et al. SCHIZOPHRENIA RESEARCH
- PDE10A Inhibitors: Novel Therapeutic Drugs for Schizophrenia
- (2011) Jan Kehler et al. CURRENT PHARMACEUTICAL DESIGN
- A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia
- (2011) Bruce J. Kinon et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia
- (2011) Matthew J. Fell et al. NEUROPHARMACOLOGY
- Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia
- (2011) Daniela Alberati et al. NEUROPHARMACOLOGY
- EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors
- (2011) Jos Prickaerts et al. NEUROPHARMACOLOGY
- Glutamate in Schizophrenia: A Focused Review and Meta-Analysis of 1H-MRS Studies
- (2011) Anouk Marsman et al. SCHIZOPHRENIA BULLETIN
- Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
- (2010) John H. Krystal et al. CNS DRUGS
- Targeting α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia
- (2010) Mihaly Hajos et al. CURRENT PHARMACEUTICAL DESIGN
- Neuronal Nicotinic Acetylcholine Receptors - Targets for the Development of Drugs to Treat Cognitive Impairment Associated with Schizophrenia and Alzheimers Disease
- (2010) Simon Haydar et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Animal models of neuropsychiatric disorders
- (2010) Eric J Nestler et al. NATURE NEUROSCIENCE
- Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia
- (2010) W Liu et al. PHARMACOGENOMICS JOURNAL
- Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia
- (2009) S. M. Grauer et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The neurobiology of D-amino acid oxidase and its involvement in schizophrenia
- (2009) L Verrall et al. MOLECULAR PSYCHIATRY
- The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
- (2009) O. D. Howes et al. SCHIZOPHRENIA BULLETIN
- Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia
- (2008) C. J. Schmidt et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Evidence for the Role of Metabotropic Glutamate (mGlu)2 Not mGlu3 Receptors in the Preclinical Antipsychotic Pharmacology of the mGlu2/3 Receptor Agonist (-)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic Acid (LY404039)
- (2008) M. J. Fell et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started